{"product_id":"dtil-vrio-analysis","title":"Precision BioSciences, Inc. (DTIL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Precision BioSciences, Inc. (DTIL)'s enduring success! This concise VRIO analysis cuts straight to the chase, revealing precisely how its core assets stack up on the dimensions of Value, Rarity, Inimitability, and Organization. Don't just wonder about their competitive advantage - read the distilled findings below to see if they truly possess sustainable superiority.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: Proprietary ARCUS® Genome Editing Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core engine of Precision BioSciences, Inc. (DTIL), the ARCUS® platform, and whether it provides a durable moat. Honestly, the platform’s technical profile and the IP protection around it suggest a strong, long-term advantage, provided the clinical programs deliver.\u003c\/p\u003e\n\n\u003ch\u003eValue: Precision Editing for High Unmet Need\u003c\/h\u003e\n\u003cp\u003eThe ARCUS® platform is valuable because it enables precise, defined gene edits - insertion, elimination, and excision - for \u003cem\u003ein vivo\u003c\/em\u003e (inside the body) therapies. This capability directly targets serious conditions like chronic Hepatitis B (HBV) and Duchenne Muscular Dystrophy (DMD). For example, the lead program, PBGENE-HBV, is showing durable antiviral activity in its Phase 1 trial, with Cohort 3 dosing initiated in the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e. Also, the DMD program is on track for an Investigational New Drug (IND) filing by the end of \u003cstrong\u003e2025\u003c\/strong\u003e. This utility is clear: it addresses high unmet needs with a novel mechanism.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Distinctive Mechanism in a Crowded Field\u003c\/h\u003e\n\u003cp\u003eIn the gene editing space, which is getting crowded, ARCUS stands out. Its rarity stems from its specific cutting mechanism, smaller physical size, and simpler structure compared to other systems. This difference is key; it may allow for more intended, defined therapeutic outcomes. While other platforms exist, the specific technical advantages of ARCUS nucleases are not easily replicated.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Strong Patent Protection\u003c\/h\u003e\n\u003cp\u003eReplicating the core technology is difficult and slow, which is a good sign for your investment thesis. The platform’s core is protected by patents. Specifically, the U.S. Patent No. 12,410,418, covering the PBGENE-HBV ARCUS nuclease, has composition of matter claims that run until \u003cstrong\u003eMarch 2042\u003c\/strong\u003e. That’s a long runway of exclusivity for their lead asset. What this estimate hides is the difficulty in replicating the specialized R\u0026amp;D know-how built over years, which is an intangible barrier.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Pipeline Leverage and Financial Focus\u003c\/h\u003e\n\u003cp\u003ePrecision BioSciences, Inc. shows high organization in leveraging this platform. It underpins their entire wholly-owned pipeline, including PBGENE-HBV and PBGENE-DMD, plus partnered programs like the OTC deficiency therapy. Financially, they are managing resources to hit these milestones; as of September 30, 2025, they held about \u003cstrong\u003e$71.2 million\u003c\/strong\u003e in cash, and they believe their current capital, plus operational receipts and ATM availability, extends their cash runway into the second half of \u003cstrong\u003e2027\u003c\/strong\u003e. Research and development expenses for Q3 2025 were \u003cstrong\u003e$13.4 million\u003c\/strong\u003e, showing continued investment into the platform’s programs.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage Scoring\u003c\/h\u003e\n\u003cp\u003eHere’s the quick math on the VRIO assessment for the ARCUS platform itself:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eScore (1-4)\u003c\/th\u003e\n\u003cth\u003eCompetitive Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (Costly to Imitate)\u003c\/td\u003e\n\u003ctd\u003eYes (Patents)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Exploited)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage Potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe platform itself scores high, but the final advantage hinges on the clinical execution. If the IND for PBGENE-DMD is filed by year-end \u003cstrong\u003e2025\u003c\/strong\u003e and PBGENE-HBV continues to show curative potential, the advantage becomes sustained. If onboarding takes 14+ days for a partner program, clinical trial timelines could slip, which is a risk to the Organization score.\u003c\/p\u003e\n\u003cp\u003eThe platform’s capabilities are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGene insertion for adding function.\u003c\/li\u003e\n\u003cli\u003eElimination of viral DNA (e.g., HBV cccDNA).\u003c\/li\u003e\n\u003cli\u003eExcision of defective gene segments (e.g., DMD).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: PBGENE-HBV Clinical Program \u0026amp; Data\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nPotential first-in-class curative treatment for chronic Hepatitis B, with Q3 2025 data showing a durable HBsAg reduction of approximately \u003cstrong\u003e50%\u003c\/strong\u003e in one patient at 9 months post-initial dose from Cohort 1 (\u003cstrong\u003e0.2 mg\/kg\u003c\/strong\u003e). \n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nMedium. Other companies target HBV, but Precision BioSciences’ dual mechanism (eliminating cccDNA and inactivating integrated HBV DNA) is unique. Estimated baseline HBsAg levels in the study ranged from \u003cstrong\u003e370\u003c\/strong\u003e to \u003cstrong\u003e11,813 IU\/mL\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. Competitors can pursue similar targets, but the clinical data generated so far is unique to Precision BioSciences.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. Dosing Cohort \u003cstrong\u003e3 (0.8 mg\/kg)\u003c\/strong\u003e initiated in Q3 2025 and securing a late-breaking oral presentation at AASLD 2025 show strong clinical execution. As of the October 31, 2025 data cutoff, \u003cstrong\u003enine\u003c\/strong\u003e evaluable patients had been dosed across three ascending cohorts with a total of \u003cstrong\u003e22\u003c\/strong\u003e administered doses.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. Patent No. \u003cstrong\u003e12,410,418\u003c\/strong\u003e covering PBGENE-HBV granted, with expiration in March \u003cstrong\u003e2042\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected cash runway extended to the second half of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe execution across dose escalation is summarized below:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCohort\u003c\/th\u003e\n\u003cth\u003eDose (mg\/kg)\u003c\/th\u003e\n\u003cth\u003ePatients Dosed (as of Oct 31, 2025)\u003c\/th\u003e\n\u003cth\u003eBest HBsAg Reduction Observed\u003c\/th\u003e\n\u003cth\u003eDose Administration Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e69%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCompleted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e66%\u003c\/strong\u003e (following third dose)\u003c\/td\u003e\n\u003ctd\u003eCompleting dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData pending\/early\u003c\/td\u003e\n\u003ctd\u003eEarly reductions within \u003cstrong\u003e2 weeks\u003c\/strong\u003e of first dose\u003c\/td\u003e\n\u003ctd\u003eDosing initiated in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. Clinical progress is a moving target; sustained advantage depends on hitting the next data readout, with completion of Cohort 3 dosing expected in Q1 \u003cstrong\u003e2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: PBGENE-DMD Development Program\n\u003c\/h2\u003e\n\u003cp\u003e\nPBGENE-DMD Development Program\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Targets the majority of Duchenne Muscular Dystrophy patients with an in vivo excision approach, a massive market need. The program is designed to potentially benefit up to \u003cstrong\u003e60%\u003c\/strong\u003e of DMD patients afflicted with mutations in exons 45-55. The 7MM Duchenne Muscular Dystrophy market size was around USD \u003cstrong\u003e2,150 million\u003c\/strong\u003e in 2023.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e In vivo gene editing for DMD is a high-value, difficult-to-achieve goal, making this asset rare. Preclinical data in mice showed restoration of up to \u003cstrong\u003e85%\u003c\/strong\u003e dystrophin-positive cells in key muscles.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e The complexity of in vivo delivery and the specific excision required are hard to copy quickly.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is focused on filing the Investigational New Drug (IND) application by the end of \u003cstrong\u003e2025\u003c\/strong\u003e. The company expects its cash runway to extend into the second half of \u003cstrong\u003e2027\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. If the IND is cleared and Phase 1 starts in H1 \u003cstrong\u003e2026\u003c\/strong\u003e, the first-mover advantage in this specific in vivo approach will be significant.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeted Patient Population Share\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e60%\u003c\/strong\u003e of DMD patients\u003c\/td\u003e\n\u003ctd\u003eMutations in exons 45-55\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Efficacy (Mouse Model)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e85%\u003c\/strong\u003e dystrophin-positive cells\u003c\/td\u003e\n\u003ctd\u003eKey muscles treated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND\/CTA Filing Target\u003c\/td\u003e\n\u003ctd\u003eEnd of \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnticipated timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Initiation Target\u003c\/td\u003e\n\u003ctd\u003eFirst half of \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePending IND clearance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Clinical Data Expected\u003c\/td\u003e\n\u003ctd\u003eSecond half of \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnticipated timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto the second half of \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEnables milestones for PBGENE-HBV and PBGENE-DMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS DMD Patient Population (2023)\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e17,200\u003c\/strong\u003e prevalent cases\u003c\/td\u003e\n\u003ctd\u003eLargest prevalent population in 7MM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7MM DMD Market Value (2023)\u003c\/td\u003e\n\u003ctd\u003eUSD \u003cstrong\u003e2,150 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nKey Regulatory\/Program Milestones:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nReceived \u003cstrong\u003eRare Pediatric Disease Designation\u003c\/strong\u003e from the FDA in June 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nMechanism utilizes \u003cstrong\u003etwo complementary ARCUS nucleases\u003c\/strong\u003e delivered in a single AAV.\n\u003c\/li\u003e\n\u003cli\u003e\nPreclinical data showed sustained muscle strength improvements up to \u003cstrong\u003enine months\u003c\/strong\u003e post-treatment in mice.\n\u003c\/li\u003e\n\u003cli\u003e\nResearch and Development Expenses for Q3 ended September 30, 2025, were USD \u003cstrong\u003e13.4 million\u003c\/strong\u003e, with an increase primarily due to the PBGENE-DMD program.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: ARCUS IP Portfolio with 2042 Patent Expiry\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eARCUS IP Portfolio with 2042 Patent Expiry\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: Provides a long-term legal moat around the core technology, securing future revenue streams and deterring direct competition.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: High. U.S. patent protection extending into \u003cstrong\u003eMarch 2042\u003c\/strong\u003e for the lead program is a substantial, rare asset for a clinical-stage firm.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Very High. Patents are the ultimate barrier to imitation in this sector.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: Medium. The IP is strong, but the organization must actively defend it, which costs money.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained. This is a classic source of sustained advantage in pharma\/biotech.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Asset\/Metric\u003c\/th\u003e\n\u003cth\u003eKey Date\/Value\u003c\/th\u003e\n\u003cth\u003eRelated Financial Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGENE-HBV Patent Expiry (US)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 2042\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (FY 2023): \u003cstrong\u003e$53.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGENE-PMM Patent Expiry (US Allowance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 2042\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q3 2025): \u003cstrong\u003e$13.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Expectation\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eSecond Half of 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents, Restricted Cash (Sep 30, 2025): Approx. \u003cstrong\u003e$71.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG Therapeutics Upfront Payment (Jan 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.5 million\u003c\/strong\u003e (Cash portion)\u003c\/td\u003e\n\u003ctd\u003eImugene Milestone Payment (Oct 2025): \u003cstrong\u003e$8 million\u003c\/strong\u003e (Cash and stock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nThe ARCUS platform underpins multiple pipeline candidates:\n\u003cul\u003e\n\u003cli\u003ePBGENE-HBV (Phase 1 ELIMINATE-B trial dosing Cohort 3 initiated in Q3 2025)\u003c\/li\u003e\n\u003cli\u003ePBGENE-PMM (targeting m.3243A\u0026gt;G mutation)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\nIntellectual property defense is an ongoing operational cost reflected in General and Administrative Expenses, which were \u003cstrong\u003e$7.3 million\u003c\/strong\u003e for the quarter ended September 30, 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: Cash Runway Extending to H2 2027\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProvides financial stability to reach critical clinical milestones (like \u003cstrong\u003ePBGENE-DMD IND filing\u003c\/strong\u003e and data readouts) without immediate, dilutive financing pressure.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eExpected data readouts from \u003cstrong\u003e3\u003c\/strong\u003e clinical programs between the end of 2025 and the second half of 2027.\u003c\/li\u003e\n\u003cli\u003eDosing started in Cohort \u003cstrong\u003e3\u003c\/strong\u003e of the \u003cstrong\u003eELIMINATE-B\u003c\/strong\u003e trial (\u003cstrong\u003ePBGENE-HBV\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003ePreclinical data showed durable improvements in muscle function for \u003cstrong\u003eDMD\u003c\/strong\u003e mouse models.\u003c\/li\u003e\n\u003cli\u003eAnticipated $8 million milestone payment from Imugene in the fourth quarter of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nMedium. Having $71.2 million in cash as of September 30, 2025, with a runway into the second half of 2027 is good for a company burning cash.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash (Jun 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$85 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$108.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Per Share (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(1.84)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow. Cash is fungible; competitors can raise capital, though Precision BioSciences’ recent cost cuts help.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. The July 2025 operating efficiencies show management is actively managing the burn rate.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eOperating efficiency program initiated in July 2025.\u003c\/li\u003e\n\u003cli\u003eAimed at reducing annual cash operating expenses by approximately $25 million in each of 2026 and 2027 compared to the 2025 annual cash expense level.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative Expenses decreased to $7.3 million for the quarter ended September 30, 2025, from $8.8 million for the quarter ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company believes its current cash and expected operational receipts\/ATM availability extend the runway into H2 2027.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. This advantage erodes as time passes; they must hit milestones before the runway ends.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: Strategic Partner Ecosystem (Imugene \u0026amp; iECURE)\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eGenerates non-dilutive capital and validates the ARCUS platform via external development efforts.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eProgram Focus\u003c\/td\u003e\n\u003ctd\u003eKey Financial\/Statistical Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImugene\u003c\/td\u003e\n\u003ctd\u003eEx Vivo CAR T (azer-cel)\u003c\/td\u003e\n\u003ctd\u003eReceived $8 million milestone payment on October 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiECURE\u003c\/td\u003e\n\u003ctd\u003eIn Vivo Gene Insertion (ECUR-506)\u003c\/td\u003e\n\u003ctd\u003eCompleted final toxicology studies; IND filing anticipated by end of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe initial upfront economics from the Imugene transaction were valued at $21 million, comprising $8 million in cash and a $13 million convertible note. Precision is eligible to receive up to $227 million in total milestone payments from Imugene for azer-cel, plus double-digit royalties on sales.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHaving active, milestone-paying partners for both ex vivo (Imugene) and in vivo (iECURE) programs is a good sign.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImugene's azer-cel trial is actively enrolling patients at ten U.S. sites and five sites in Australia.\u003c\/li\u003e\n\u003cli\u003eiECURE's ECUR-506 is in a first-in-human trial (OTC-HOPE) for neonatal onset ornithine transcarbamylase (OTC) deficiency.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePartnerships are based on deal-making, not unique internal resources.\u003c\/p\u003e\n\u003cp\u003eThe ARCUS platform's capabilities, such as gene insertion, elimination, and excision, are the core technology, but the specific deal terms and partner relationships are not inherently inimitable.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company successfully monetizes non-core assets and validates its technology through partners.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of September 30, 2025, Precision held approximately $71.2 million in cash, cash equivalents, and restricted cash.\u003c\/li\u003e\n\u003cli\u003eThe company expects its cash runway, bolstered by partner receipts, to extend into the second half of 2027.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\u003cp\u003ePartner value depends on the success of the partnered assets, such as Imugene advancing azer-cel toward a pivotal trial discussion with the FDA.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: FDA Fast Track Designation for PBGENE-HBV\n\u003c\/h2\u003e\n\u003ch3\u003eFDA Fast Track Designation for PBGENE-HBV\u003c\/h3\u003e\n\u003cp\u003eThe U.S. Food and Drug Administration (FDA) granted Fast Track designation for PBGENE-HBV on April 15, 2025.\u003c\/p\u003e\n\u003ch4\u003eValue\u003c\/h4\u003e\n\u003cp\u003eAccelerates development and review timelines with the FDA, potentially bringing a treatment to market faster, which is crucial for a chronic disease affecting an estimated \u003cstrong\u003e300 million\u003c\/strong\u003e people worldwide.\u003c\/p\u003e\n\u003ch4\u003eRarity\u003c\/h4\u003e\n\u003cp\u003eMedium. While not unique, achieving this designation for an \u003cem\u003ein vivo\u003c\/em\u003e editing therapy is a significant regulatory hurdle cleared. The program is the first and only potentially curative gene editing program specifically designed to eliminate cccDNA and inactivate integrated HBV DNA to enter clinical investigation.\u003c\/p\u003e\n\u003ch4\u003eImitability\u003c\/h4\u003e\n\u003cp\u003eHigh. This is granted by the FDA based on unmet need and early data, not easily copied by competitors. The underlying ARCUS nuclease technology has patent protection extending until March \u003cstrong\u003e2042\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch4\u003eOrganization\u003c\/h4\u003e\n\u003cp\u003eHigh. The clinical data presented was strong enough to warrant this designation. Initial data from the Phase 1 ELIMINATE-B trial (NCT06680232) showed that in the lowest dose cohort (\u003cstrong\u003e0.2 mg\/kg\u003c\/strong\u003e), all three patients demonstrated steep declines in hepatitis B surface antigen (HBsAg) at day 14. The company reported a current ratio of \u003cstrong\u003e3.45\u003c\/strong\u003e as of November 2025 and extended its expected cash runway to the second half of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company's financial position as of June 30, 2025, included approximately \u003cstrong\u003e$84.8 million\u003c\/strong\u003e in cash, cash equivalents, and restricted cash, against a reported negative net income of \u003cstrong\u003e$83.6 million\u003c\/strong\u003e over the last twelve months.\u003c\/p\u003e\n\u003ch4\u003eCompetitive Advantage\u003c\/h4\u003e\n\u003cp\u003eTemporary. It speeds up the race, but the advantage disappears upon approval or if a competitor gets a similar designation. The stock price increased more than \u003cstrong\u003e8%\u003c\/strong\u003e following the announcement of the designation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Status\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFast Track Designation Date\u003c\/td\u003e\n\u003ctd\u003eApril 15, 2025\u003c\/td\u003e\n\u003ctd\u003eFDA Granting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLowest Dose Level Tested (Cohort 1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.2 mg\/kg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 1 ELIMINATE-B Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest HBsAg Reduction (Cohort 1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47-69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt Day 14\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvidence of Viral DNA Editing\u003c\/td\u003e\n\u003ctd\u003eObserved\u003c\/td\u003e\n\u003ctd\u003eOne patient in Cohort 2 (\u003cstrong\u003e0.4 mg\/kg\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003eSecond half of \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExtended to enable data readouts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Valuation\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$80 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: Operational Efficiency \u0026amp; Cost Structure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduced annual operating expenses through July 2025 cuts, leading to a lower cash burn rate and extending the runway into the \u003cstrong\u003esecond half of 2027\u003c\/strong\u003e. Cash, Cash Equivalents, and Restricted Cash stood at \u003cstrong\u003e$71.2 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Most companies implement cost-cutting when needed, but the result - extending runway to \u003cstrong\u003eH2 2027\u003c\/strong\u003e - is valuable. The cost reduction program implemented in July 2025 aimed to reduce annual cash operating expenses by approximately \u003cstrong\u003e$25 million\u003c\/strong\u003e per year in 2026 and 2027 compared to the 2025 annual cash expense level.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can cut costs, but the specific structure and timing of Precision BioSciences’ cuts are internal. The reduction in operating expenses was realized through cuts in early research and general \u0026amp; administrative expenses.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management demonstrated the ability to reduce G\u0026amp;A expenses to \u003cstrong\u003e$7.3 million\u003c\/strong\u003e in Q3 2025 without hurting R\u0026amp;D spend, which increased to \u003cstrong\u003e$13.4 million\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a management discipline, not a structural barrier to entry.\u003c\/p\u003e\n\n\u003cp\u003eThe operational efficiency measures implemented are reflected in the following comparative financial data:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$8.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$13.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$21.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$108.5 million (End of 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe impact of the July 2025 operating efficiencies on quarterly spending is further detailed:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Operating Expenses fell to \u003cstrong\u003e$20.7 million\u003c\/strong\u003e in Q3 2025, compared to \u003cstrong\u003e$21.9 million\u003c\/strong\u003e in Q2 2025 and \u003cstrong\u003e$21.9 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses decreased primarily due to employee-related costs.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses increased primarily due to the PBGENE-DMD program.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrecision BioSciences, Inc. (DTIL) - VRIO Analysis: In Vivo Gene Editing Expertise\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIn Vivo Gene Editing Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Deep institutional knowledge in designing, manufacturing, and delivering gene editing components inside the body, which is far more complex than ex vivo work.\u003c\/p\u003e\n\u003cp\u003eRarity: High. True, proven in vivo delivery expertise is a scarce resource in the biotech world.\u003c\/p\u003e\n\u003cp\u003eImitability: High. This is tacit knowledge built over years of R\u0026amp;D, not easily codified or bought.\u003c\/p\u003e\n\u003cp\u003eOrganization: High. This expertise is the foundation for the entire pipeline, from PBGENE-HBV to PBGENE-DMD.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained. Specialized, hard-won scientific know-how is a bedrock advantage.\u003c\/p\u003e\n\n\u003cp\u003eFinance: 13-Week Cash Flow View Incorporation (Post-November 2025 Offering)\u003c\/p\u003e\n\n\u003cp\u003eThe recent underwritten offering announced on November 10, 2025, aimed to raise approximately \u003cstrong\u003e$75 million\u003c\/strong\u003e in gross proceeds from the sale of common stock and warrants, with pre-funded warrants also included in the structure. This capital injection follows a reported End Cash Position of \u003cstrong\u003e$108.47M\u003c\/strong\u003e as of Q3 2025. The net proceeds are intended to fund ongoing and planned research and development, working capital, and general corporate purposes. The issuance of new shares and equivalents was noted to potentially \u003cstrong\u003emore than double\u003c\/strong\u003e the outstanding share count.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Nov 2025 Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnnounced November 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnd Cash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$108.47M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$-15.27M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$87.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast Twelve Months (TTM)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Pre-Offering Context)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$80 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAround November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding (Historical Base)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13,257 K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrior to Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe ARCUS® platform underpins the in vivo pipeline, targeting complex genetic and infectious diseases:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePBGENE-HBV for chronic hepatitis B virus (HBV) aiming for functional cure through elimination of covalently closed circular DNA and inactivation of integrated HBV DNA.\u003c\/li\u003e\n\u003cli\u003ePhase 1 ELIMINATE-B trial data showed substantial reductions in hepatitis B surface antigen (HBsAg) levels, with the \u003cstrong\u003e0.8 mg\/kg\u003c\/strong\u003e dose cohort showing significant reduction after a single dose.\u003c\/li\u003e\n\u003cli\u003ePBGENE-DMD for Duchenne Muscular Dystrophy utilizing an excision approach.\u003c\/li\u003e\n\u003cli\u003ePBGENE-3243 for m.3243 associated mitochondrial myopathy.\u003c\/li\u003e\n\u003cli\u003ePartnered program ECUR-506 for OTC deficiency.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516153782421,"sku":"dtil-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dtil-vrio-analysis.png?v=1740207289","url":"https:\/\/dcf-model.com\/es\/products\/dtil-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}